Previously, we identified an HBV binding factor (HBV-BF), a 50-kDa serum glycoprotein which interacts with HBV envelope proteins and which is also located in the membrane of normal human hepatocyte (A. Budkowska et al. (1993) J. Virol. 67, 4316). Here we show that HBV-BF is a neutral metalloproteinase which shares substrate specificity and properties with a newly described family of membrane type matrix metalloproteinases. HBV-BF treatment of the HBV resulted in the cleavage of the N-terminal part of the middle HBV envelope protein at the pre-S2(136-141) amino acid sequence VRGLYF/L (containing a single arginine cleavage site). HBV-BF affected the reactivity of the large HBV protein with pre-S1-specific MAbs, probably inducing the conformational change of the pre-S1 domain. The HBV-BF-digested virus remained morphologically intact with unchanged S antigenic determinants. The structural modifications of the viral envelope proteins induced by HBV-BF enabled cell membrane attachment and viral entry into the T-lymphocyte. Both processes were blocked by the metalloproteinase inhibitor 1,10 phenanthroline. Thus, the host-dependent proteolytic activation of the envelope proteins seems to be essential for the HBV entry into the cell. HBV-BF under a membrane bound or a secreted form could be (one of) the molecule(s) responsible for the HBV proteolytic activation. ᭧ 1997 Academic Press
INTRODUCTION
ments of the viral genome, are located at the surface of virions and of subviral particles. They may act as viral The entry of enveloped viruses into their target cells attachment proteins in the interaction of HBV with the requires the binding of the virus to one or more cellular membrane receptor(s) on the surface of the hepatocyte receptor(s) and the fusion of the envelope with the target (8, 9, 28) . The S protein is probably fusogenic (37) . cell membrane. In some cases the same molecule re-
The early stages of the HBV infection remain unknown sponsible for virus attachment can also mediate internaldue to the failure to cultivate HBV in vitro. The major ization. For other viruses such as Sendai virus, influenza target organ of HBV is the liver. Hepatocytes are appar-A virus, Newcastle disease virus, murine coronavirus, ently the only cells susceptible and permissive to infechuman immunodefficiency virus type 1, and rotaviruses tion, although viral antigens and DNA have been de-(14, 26) proteolytic cleavage of viral surface glycoproteins tected in many extrahepatic tissues. Cellular components by host cell proteases is necessary for viral infection.
involved in the entry of HBV into its target cell have not The cleavage results in the exposure of a hydrophobic been identified and little is known about the biological stretch of amino acids which acts as the mediator of bases of its restricted host range and tissue tropism. membrane fusion and determines tissue tropism of these Various molecules have been described as candidates viruses, especially if the virus utilizes ubiquitous molefor HBV receptors (7, 12, 28, 30, 42) ; however, there is cules as receptors.
no evidence that a particular component mediates proHepatitis B virus (HBV) is a member of the hepadnaviductive infection. Recent data have shown that peripheral rus family. It is composed of a 3.2-kb DNA genome, a mononuclear cells of HBV-infected patients exhibit adnucleocapsid core and a viral envelope, containing three sorbed viral particles but not the replicating virus (15), coterminal viral glycoproteins termed large (L), medium thus raising the question of the presence of HBV recep-(M), and small (S). These HBV surface proteins are entors on human lymphoid cells and the possibility of the coded by a single open reading frame-gene S-com-HBV entry into this type of cell. posed of the pre-S1, pre-S2, and S regions with alternaWe have described in human serum a 50-kDa moletive translational initiation sites. The domains of the M cule, called ''HBV-binding factor'' (HBV-BF) which interand L proteins, encoded by the pre-S1 and pre-S2 fragacts with the pre-S1 and pre-S2 epitopes of the viral envelope (5) . The immunochemical properties of this mol-teins, and the localization of an antigenically related comSuperose 12 column (Pharmacia) and by SDS-PAGE. As previously described (5) the purified HBV-BF was eluted ponent in the membrane of the human hepatocyte suggested that HBV-BF may be involved in the HBV entry from the HPLC column as a single peak of activity of a molecular mass of 50 kDa, corresponding to a single into the cell. Here we show that HBV-BF displays the properties of a member of recently described membranepeak of protein (O.D. 0.2 1 10 03 ). The trace amounts of protein components of a molecular mass of 10 kDa or type matrix metalloproteinase family (38) and induces structural modifications of the viral envelope enabling less were eluted after HBV-BF peak and did not show any reactivity with HBV envelope. No bands or only a attachment and internalization of HBV into the T-lymphocyte cell line.
weak 50-kDa protein band could be detected in the purified HBV-BF preparation after SDS-PAGE under nonreThe proteolytic activation of the envelope proteins with an enzyme identical or related to HBV-BF seems to be ducing conditions followed by a silver staining. required for HBV entry into the cell. Proteolysis which Determination of the inhibitory effect of HBV-BF on triggers a conformational change of the HBV envelope the binding of MAbs to the HBV envelope proteins might induce the exposure of the fusogenic sequence necessary for the fusion of the viral envelope with the Inhibition assays for detection of HBV-BF were carried cell plasma membrane. Thus, the presence of this type out as previously described (5) . The assays were based of enzyme in the active form in the membrane or in the on the inhibition by HBV-BF of the binding of horseradish vicinity of the target cell could be determinant for this (HRPO)-labeled MAbs to the pre-S1, pre-S2, and S region process.
encoded epitopes on HBV or on recombinant m-HBsAg particles. The wells of microtiter plates (Nunc, Roskilde, MATERIAL AND METHODS Denmark) were coated with HBV or m-HBsAg particles at a concentration of 1 mg of protein per milliliter. The Cell culture plates were overcoated with 1% bovine serum albuminThe human T lymphoblastoma cell line CEM was cul-0.05% Tween 20 in phosphate-buffered saline. Samples tured in a RPMI 1640 medium (Gibco BRL) supplemented tested for HBV-BF activity were incubated for 2 hr at 37Њ with 10% of fetal bovine serum, 2 mM L-glutamine, 100 on HBV or m-HBsAg-coated plates and after washing the units/ml of penicillin, and 100 mg/ml of streptomycin. The wells were incubated with HRPO-labeled MAbs and then medium was changed three times a week.
with o-phenylenediamine as a substrate. MAbs used in the assay and their epitope specificity are detailed in HBV and recombinant HBsAg particles Table 1 . MAbs Ma18/7 (39) and E21/14 (22) were kindly HBV particles were purified from the plasma of HBV provided by W. H. Gerlich, MAbs F124 (4), F376 (6, 26) carriers by a sequence of ultracentrifugations as pre-39-10 (6), and 5a-19 (6) were produced in our laboratory, viously described (5). Recombinant HBsAg particles (mMAbs 144 and 112 were kindly provided by J. P. BourHBsAg) were produced in Chinese hamster DHFR 0 ovary geois (Sanofi Diagnostics Pasteur) and MAb E6 (22) by cells transfected with a plasmid encoding the pre-S re-B. Porstmann. gion of the S gene of HBV and murine dihydrofolate reThe absorbance (A) values at 492 nm were measured ductase (23) . These particles contained three polypepby ELISA in the linear range of the assay and the results tides of a molecular mass of 22, 26, and 43 kDa correwere expressed as percentage inhibition calculated as sponding to the small (24 and 26 kDa) and the middle follows: (34 kDa) envelope proteins. Polypeptides of 26 and 34 Percentage inhibition kDa were glycosylated. Recombinant m-HBsAg particles were purified by the producer and were kindly provided Å A negative control 0 A test sample A negative control 0 A positive control 1 100 by R. Vinas (Pasteur Mé rieux).
The negative controls were at the absorbance values Purification of HBV-BF 1.6-1.9 and positive controls at 0.05 to 0.2. HBV-BF was purified from human serum as previously described (5) . Globulins were precipitated from serum Biomolecular interaction analysis (BIA core) of the with 50% ammonium sulfate, followed by ion exchange HBV-BF activity chromatography (DE 52, Whatman) and gel permeation with a series of three Sephacryl S200 columns (Phar-HBV or recombinant m-HBsAg particles were immobilized on the sensor chip CM5 directly or by the intermedimacia, Sweden). The final preparation was incubated with insoluble rabbit antibodies to human IgG to remove ate of 39-10 MAb anti-HBs using the procedure described by Jonsson et al. (13) . The carboxylated dextran contaminating IgG or its fragments.
The level of purity of HBV-BF was determined using matrix of the sensor chip was activated using N-hydroxysuccinimide (NHS) and N-ethyl-N-(3-diethylaminopropyl) high-performance liquid chromatography (HPLC) with a carbodiimide (EDC) (Pharmacia Biosensor, Uppsala, (10 mM EDTA 10 mM Tris-HCl, pH 7.8, 150 mM NaCl, 0.2% SDS) for 2 hr at 45Њ. The samples were extracted Sweden). The ligand 0 m-HBsAg particles (30 ml) at a concentration of 100 mg/ml in a buffer, pH 5.0, were inwith phenol/chloroform, and the DNA was precipitated with ethanol and resuspended in 20 ml of 10 mM Trisjected followed by 30 ml of 1 M ethanolamine hydrochloride at pH 8.5, to deactivate the unreacted groups. SubseHCl, pH 7.4, containing 1 mM EDTA. The samples were then analyzed by PCR with oligonucleotide primers quently, 25 ml of the purified preparation of HBV-BF in PBS were injected over the surface of the sensor chips.
MD027 (nt position 1861-1880) and MD 031 (nt position 2286-2270) corresponding to the conserved sequences Any change in the surface concentration resulting from the interaction of HBV-BF with HBV or recombinant mof the C gene. The PCR products were separated by electrophoresis HBsAg particles was detected as an optical phenomenon of the surface plasmon resonance (SPR) signal exin a 1.2% agarose gel containing ethidium bromide and were analyzed by Southern blotting on a Hybond-N mempressed in resonance units (RU). The continuous display of RU as a function of time was referred to as a sensobrane (Amersham, England). The plasmid (pCP10) containing two complete head to tail copies of HBV genome gram. The effect of the action of HBV-BF on the immobilized particles was investigated by incubation of the sen-(subtype ayw) cloned into pBR322 at the EcoRI site was labeled with dUTP-fluorescein using the ECL random sor chips with a series of MAbs directed to the pre-S and S epitopes.
priming kit (RPMN3040, Amersham) and used as a probe. The hybridized fluorescein-labeled probe was detected Analysis of the effect of proteinase inhibitors on HBVon the blots with a horseradish peroxidase-labeled anti-BF activity fluorescein antibody, and revealed by chemoluminescence (ECL, Amersham). Using this method, 0.01-0.001 Inhibitors of different groups of proteases were mixed with purified HBV-BF prior to incubation with recombinant fg/sample of cloned HBV DNA (pCP10) could be detected corresponding to 15-150 copies of the genome. m-HBsAg or HBV. The protease inhibitors were: pepstatin, leupeptin, E64, chymostatin, phenylmethanesulfoDetection of ccc DNA nyl fluoride (PMSF), antipain, and soybean trypsin inhibitor (Behringer Mannheim Biochemicals); 1,10 phenanCovalently closed circular DNA (cccDNA) in extracts throline, EDTA, phosphoramidon, and aprotinin (Sigma of cultured cells was detected as previously described Chemical Co.) and were used at concentrations listed in (19). Briefly, DNA was extracted and precipitated as Table 2 . The effect of the inhibitor was expressed as above and analyzed by PCR using two pairs of primers. percentage of the residual HBV-BF activity measured by
The choice of primers was determined by the position ELISA as compared to the activity of HBV-BF mixed with of the minus strand gap between nucleotides 1823 and PBS instead of inhibitor. To prevent pairing between newly synthesized DNA protein/ml). HBV-BF-treated and control samples were strands initiated by primers C0 and S/ when RC-DNA preincubated for 1 hr at 37Њ before inoculation of the was the template, the three primers were designed to cells. In some experiments, the HBV-BF inhibitor, 10 mM hybridize above 72Њ (average T m of 80Њ) and were used 1,10-phenanthroline, was included in the reaction mixin excess. The detection limits of this technique after ture. The effect of HBV-BF on the envelope proteins was Southern blot and hybridization for both pairs of primers controlled by ELISA using pre-S-specific MAbs as deranged from 0.1 to 1 fg/sample when the plasmid pCP10 scribed above. The inoculated cells were washed as described above was used as a template (19). above, transferred to a complete culture medium containing 10% fetal calf serum, and grown at 37Њ. In some Isolation of cell surface components experiments the cells were subsequently digested with 0.5% trypsin to remove virus adsorbed onto the cell surCell surface proteins were isolated by a modification of the method of Maisner et al. (20) . The cells were biotin face. Aliquots of inoculated cells were harvested for PCR analysis at days 1 to 13.
labeled, washed, and lysed in a buffer containing 1% Triton X-100, 0.1% SDS, 1% DOC, 0.15% NaCl, and proteDetection of HBV-DNA in the inoculated cells ase inhibitors. The labeled components were isolated by adsorption on insoluble streptavidin-agarose and sepaAliquots of inoculated cells (or cellular fractions) were digested with 500 mg/ml of proteinase K in a lysis buffer rated by centrifugation. SDS-polyacrylamide gels copolymerized with 1 mg/ml SDS, and bromophenol blue. Electrophoretic migration of gelatin as described above. was carried out on 7% SDS-polyacrylamide gels and copolymerized with 1 mg/ml of gelatin or casein as preWestern immunoblotting viously described (11, 41) . SDS was extracted with Triton Specimens were solubilized in a buffer containing 2% X-100 and the gel was incubated overnight at 37Њ in a SDS, 5% 2-mercaptoethanol, 0.01% bromophenol blue, reaction buffer containing 50 mM Tris-HCl, pH 7.4, 5 and 20% glycerol for 2 min at 100Њ. Proteins were sepamM CaCl 2 , and 5 mM ZnCl 2 . To investigate the effect of rated on 5-15% polyacrylamide gradient gels and elecproteinase inhibitors: 50 mM 1,10 phenanthroline, 100 troblotted onto nitrocellulose. The membrane strips were mM EDTA, 1 mM PMSF, or 2 mM N-ethylmaleimide blocked overnight at 4Њ with 5% skim milk, washed, and (NEM) were added to the reaction buffer. Gels were let to react for 1 hr at room temperature with MAbs distained with 0.5% Coomassie brilliant blue G250 in 30% luted in 1% skim milk. The MAbs used for immunoblotting methanol, and 10% acetic acid for 4 hr. This technique included anti-pre-S1 MAb 5a-19 (6), anti-pre-S2 MAbs detects clear bands, the cleaved (active) forms of en-F124 (4), and E21/14 (22) and anti-HBs MAb H166 (25) zymes as well as their inactive (uncleaved) precursors reactive with all denatured HBV envelope proteins, kindly (proenzymes) due to the exposition of the active site of provided by L. T. Mimms. the enzyme by conformational changes induced under experimental conditions as demonstrated by Herron et Electron microscopy al. (11) . This process is not, however, considered as an Two-step staining procedure was used: 400-mesh activation, where the cleavage of a propeptide results in grids coated with plastic-carbon films were placed onto the exposition of the active, enzymatic site since the real a drop of virus suspension, dried with a filter paper, and activation process can be evidenced by a decrease in finally floated on a drop of negative stain (1% phosphothe molecular weight of the analyzed molecule. tungstic acid). The specimens were observed with a JEOL JEM-1010 electron microscope. Activation of MMP-2 by HBV-BF RESULTS Conditioned media from hepatic stellate cells, conModification of the L and M envelope proteins by taining a latent form of the matrix metalloproteinase-2 (1)
HBV-BF were prepared as previously described (17, 41) . Aliquots of these preparations (15 ml) were incubated with 0.1, 1,
To define the mode of action of HBV-BF on the envelope proteins we analyzed the inhibitory activity of this or 5 ml of HBV-BF (corresponding to 8, 80, or 400 ng of protein), with or without proteinase inhibitors (10 mM molecule on the binding of MAbs directed to different epitopes on the recombinant m-HBsAg and serum HBV 1,10 phenanthroline, 10 mM EDTA, 1 mM PMSF, or 2 mM NEM) 6 hr at 37Њ and analyzed by zymography in 7%
( Table 1 ). The first series of experiments with recombi-nant m-HBsAg as a solid phase antigen demonstrated creased of about 6-8 kDa after incubation with HBV-BF, whereas the S and L HBV proteins remained unchanged that the binding of MAbs F124 and Q 19-10 specific to the N-terminal, pre-S2 epitopes (aa 120-126), was strongly (Fig. 1D ). All these data suggested that HBV-BF can be a proteininhibited (90-100%) by HBV-BF. Binding of MAbs F376 and E6 reactive with the epitopes localized in the prease cleaving the M protein within the pre-S2 sequence in recombinant as well as in the viral particles. HBV-BF S2 (aa 133-145) sequence was only partially inhibited (40-60%), whereas binding of MAb E21/14 specific to did not cleave the L protein, since the potential cleavage sites in the pre-S2 domain are not accessible in the L the C-terminal pre-S2 sequence (aa 162-168) was not blocked by HBV-BF. The reactivity of the S determinants protein (8) . However, HBV-BF hampered the reactivity of the pre-S-specific MAbs with the corresponding epitopes of HBsAg particles remained unchanged as evidenced by the binding of three different anti-S-specific MAbs.
in the L protein, suggesting that either a conformational modification or blocking of the pre-S domains occurred. These results suggested that the interaction site of HBV-BF with the pre-S2 domain is located in the central part Indeed, the large HBV protein of unchanged molecular weight, reactive with pre-S1-and pre-S2-specific MAbs of the pre-S2 region (aa 133-145) corresponding to the epitopes recognized by MAbs F376 and E6.
was evidenced by Western blotting in HBV-BF-treated HBV particles. The observed modifications did not conAnother series of experiments with complete virions as the solid phase antigen showed that HBV-BF blocked cern the S protein domain since the conformational a determinant of the HBV envelope remained immunologithe binding of the pre-S2-specific MAbs F124 and E6 to the viral particles in the same way as to the m-HBsAg cally unchanged and the electron-microscopic analysis of the HBV-BF-digested virions showed their well-con- (Table 1) . Interestingly, the binding of the MAb E21/14 specific to the C-terminal epitope of the pre-S2 domain of served structure (Fig. 2B ) in comparison with the native HBV ( Fig. 2A) . HBV was not inhibited but significantly enhanced (150-230%) following incubation with HBV-BF. This observa-
The proteinase activity of HBV-BF was further evidenced by the real-time biospecific interaction analysis (BIA core). tion suggested a conformational change and exposition of the C-terminal part of the pre-S2 domain. HBV-BF HBV or m-HBsAg particles were immobilized on the sensor chips ( Fig. 3A) and incubated with purified HBV-BF ( Fig.  blocked the binding of the two pre-S1 domain-specific MAbs Ma18/7 and 5a-19 (80-100% inhibition), recogniz-3B). Identical results were obtained for both systems involving m-HBsAg or HBV on the sensor chips: cleavage of the ing pre-S1 (28-36) and pre-S1 (36-43) aa sequence, respectively. The reactivity of the three different S regionimmobilized components could be directly observed as a release of the material from the sensor chip surface evispecific MAbs remained unchanged.
The interaction of HBV-BF with the surface HBV antigens denced by a lowering sensogram baseline after injection of HBV-BF (Fig. 3B) . HBV-BF-treated HBV and m-HBsAg was further analyzed by SDS-PAGE followed by immunoblotting with anti-pre-S antibodies (Fig. 1) . The M HBV did not bind MAb F124, suggesting that the corresponding epitopes were removed from the surface. MAb E6 bound protein (gp34/gp36) was undetectable or only weakly stained with the pre-S2-specific MAbs F124 after treatment weakly, whereas MAb 39-10 conserved its binding capacity (data not shown). These observations confirmed the partial of both m-HBsAg particles and HBV with HBV-BF (Figs. 1A and 1B), suggesting that this epitope was cleaved from the removal and stability of the corresponding epitopes, respectively. Therefore, the results obtained with BIA core M protein. It should be mentioned that the L protein is not reactive with MAb F124 since this MAb selectively binds were consistent with those obtained with ELISA and confirmed HBV-BF to be a proteolytic enzyme, which cleaved to the pre-S2 (120-126) epitope glycosylated at the Asp 123 in the M protein, whereas there is no glycan linked to the M protein. the corresponding epitope in the L protein (8, 10) . In further experiments a faster migrating 28-kDa band, corresponding
Determination of the cleavage site in the M HBV to a cleaved form of the M protein, was detected in the protein HBV-BF-treated m-HBsAg using MAb E24/14 specific to the C-terminal pre-S2 (162-168) epitope (Fig. 1C) . A protein To determine the cleavage site of HBV-BF in the pre-S2 domain, different anti-pre-S MAbs were reacted in band of the same molecular weight was detected in HBV-BF-treated virions when MAb H166, reactive with a sequen-ELISA with m-HBsAg or HBV particles prior to their incubation with HBV-BF to determine which of the pre-Stial epitope of the S domain was used for immunoblotting (Fig. 1D) .
specific MAbs could prevent the effect of HBV-BF. Most of the pre-S2-specific MAbs (F124, Q-19/10, and E 21/ In contrast, the L HBV protein (p39/gp41) of unchanged molecular weight was evidenced by immunoblotting in 14) did not affect the reactivity of HBV-BF with the pre-S2 domain; MAb F376, partially inhibited HBV-BF (about virions preincubated with HBV-BF using anti-pre-S1 MAb (5a-19). (Fig. 1B) . Immunoblotting analysis of the native 50%), whereas MAb E6 completely (100%) blocked the action of HBV-BF on the M protein. These results sugand HBV-BF-treated virions with anti-S MAb H166 confirmed that the molecular mass of the M protein degested that HBV-BF cleaves the pre-S2 domain at or reactivity of HBV-BF. As shown in Table 2 , the interaction HBV-BF shows the properties of a matrix metalloproteinase of HBV-BF with the two pre-S domains of HBV was unaffected by inhibitors of aspartic proteinases, serine proZymography analysis showed that HBV-BF migrated in teinases, and cysteine proteinases. In contrast, the effect SDS-PAGE as a 50-kDa band capable of degrading gelof HBV-BF on both M and L proteins was abolished by atin and casein, two typical substrates of the matrix metwo metalloproteinase inhibitors: EDTA and 1,10 phenantalloproteinases (Fig. 5 ). Both activities were inhibited by throline, but was unaffected by phosphoramidon, which EDTA and 1,10 phenanthroline (partially for gelatin and is a specific inhibitor of bacterial metalloproteinases and completely for casein), whereas other proteinase inhibidoes not inhibit matrix metalloproteinases. tors such as PMSF or NEM did not influence HBV-BF The optimum pH for the reactivity of HBV-BF was in activity. the neutral range and rapidly decreased at the low as HBV-BF was further incubated with conditioned mewell as at basic pH values (showing 30% of activity at dium from hepatic stellate cells which secrete a latent pH 5.0 until complete inactivation at pH 3.5 and 50% form of a matrix metalloproteinase 2 (MMP-2, gelatinase activity at pH 9.5). This feature, as well as the sensitivity A, EC 3.4.24.24) (17, 41) and the mixtures were analyzed to the action of chelating agents, suggested HBV-BF to be a member of the neutral metalloproteinase family.
by zymography. The latent form of MMP-2 (proenzyme) to prevent endocytosis, which usually occurs above 10Њ, kDa, as previously described (41), HBV-BF as a 50-kDa and to ensure that the virions remained bound and intact band and an additional band of a molecular mass of 62 during the incubation and washing procedure. Control kDa corresponded to a cleaved (activated) form of experiments were performed at 37Њ. After the binding and MMP-2. The 62-kDa band was detected in a dose-dewashing steps the cells were transferred to a complete pendent manner following treatment with increasing medium and grown at 37Њ up to 13 days after inoculation. concentrations of HBV-BF (Fig. 6A) . The activation of DNA was extracted from the cells and assayed for HBV MMP-2 by HBV-BF was inhibited by EDTA, 1,10 phenansequences by PCR. In studies of HBV internalization the throline, and partially by PMSF (Fig. 6B) . Serine proteinwashing steps were followed by trypsin digestion to elimase inhibitor NEM failed to inhibit the processing of inate any bound virus. MMP-2 by HBV-BF. All these results showed that HBV-
The extracts tested up to 13 days after inoculation BF has the enzymatic properties of a typical matrix me-(either at 4 or 37Њ) with HBV-BF-digested virus showed talloproteinase.
intense HBV-DNA bands corresponding to the amplified product of 430 bp (Fig. 7A) . In contrast no HBV-DNA Activation of the envelope proteins by HBV-BF was detected in the extracts prepared from CEM-cells enables adsorption and entry of HBV into the cell inoculated with the native, untreated HBV when tested from days 1 to 13 postinoculation. Human peripheral blood mononuclear cells can adTo investigate whether modifications of the viral envesorb viral particles (15, 33, 34) , but seem to be refractory lope proteins by HBV-BF influence either viral attachment to HBV infection (15). Therefore we addressed the quesor internalization, subcellular components were isolated tion whether the structural modifications induced by and obtained fractions assayed for the presence of HBVmetalloproteinase (HBV-BF) treatment can facilitate inter-DNA by PCR. The cell surface fraction isolated from the nalization and/or replication of HBV in T-lymphocytes. cells inoculated with metalloproteinase (HBV-BF)-digested CEM-cells were inoculated with either the native or HBV-BF-digested virus. The adsorption was carried out at 4Њ virus and harvested on day 2 postinoculation showed a 
Aspartate proteinases Pepstatin (1 mM) 9 5 9 6 Cysteine proteinases Leupeptin (100 mM) 9 2 9 4 E 64 (50 mM) 9 3 9 6 Chymostatin (100 mM) 9 6 9 6 Serine proteinases PMSF (1 mM) 9 8 9 6 Soybean trypsin inhibitor (100 mg/ml) 95 98 Aprotinin (0.6 mM) 9 4 9 5 Metalloproteinases EDTA (10 mM) 0 0 1,10 phenantroline (5 mM) 0 0 Phosphoramidon (600 mM) 9 4 9 7 Trypsin, papain, plasmin Antipain (120 mM) 9 6 9 8
Note. Purified HBV-BF was incubated with HBV particles coated on the solid phase without (control sample) or with the indicated proteinase inhibitors. The results are expressed as percentage of residual activity of HBV-BF measured by inhibition ELISA with peroxidase-labeled (a) antipre S1 Ma 18/7 and (b) anti-pre-S2 F124 MAbs as described under Material and Methods.
to family and displays the substrate specificity and the properties of a matrix metalloproteinase. HBV-BF modified strong 430-bp band of HBV-DNA (Fig. 7B) . No bands could the structure of the envelope proteins and enhanced the be observed in the membrane fraction from the cells inocucapacity of HBV to bind and enter into a T-lymphocyte lated with the native HBV, and only weak bands were cell line. First, HBV-BF cleaved the M envelope protein observed in the membrane fraction from the cells inocuin the pre-S2 sequence. Cleavage resulted in (i) the delated with the virus treated with HBV-BF in the presence crease of a molecular mass of the M protein of about 6 of 1,10 phenanthroline. These results showed that the ackDa, (ii) disappearance of the binding of the N-terminal tion of HBV-BF enhances viral binding to the cell surface pre-S2 antibodies, (iii) reduction of the binding of the and that this process is susceptible to a specific metalloMAbs directed to the central part of the pre-S2 domain, proteinase inhibitor, 1,10 phenanthroline. Furthermore, and (iiii) increase of the binding of C-terminal MAbs due HBV-DNA bands were detected up to day 13 in both cytoto the exposition of the corresponding epitopes. Cleavplasmic and nuclear fractions from cells inoculated with age of the M protein by HBV-BF was completely blocked HBV-BF-digested virus, whereas no, or only trace amounts by metalloproteinase inhibitors, but also by MAb E6 speof HBV-DNA, were found in fractions isolated from the cells inoculated with the native virus (Fig. 7C) . Therefore, HBV-BF treatment apparently facilitated not only attachment to the cell surface, but also viral internalization. This process was also inhibited by 1,10 phenanthroline, confirming the role of the metalloproteinase digestion in this event.
The cell extracts were also tested for the presence of covalently closed, circular HBV-DNA (ccc-DNA) by the strand-specific PCR. No amplification product was obtained with the ccc-DNA-specific primers, although the HBV-DNA signal did not decline with the time in the cell culture inoculated with HBV-BF-digested virus. Thus, the HBV DNA was exclusively in the RC form and there was no evidence for HBV replication in this type of cell. demonstrated (29) . This observation and the impossibility cific to the pre-S2 (136-141) epitope, suggesting that the activation of MMP-2 produced by hepatic stellate cells, via plasma membrane-dependent mechanism (41) . VRGLYF/L sequence is the cleavage site of HBV-BF in the pre-S2 domain. This aa sequence contains the arginine This process is inhibited by EDTA and can therefore be due to the metalloproteinase activity related to HBVresidue (Arg 127) and corresponds to a monobasic cleavage site present in other viral glycoproteins activated by BF, in accordance with our previous report showing the localization of a component related to the soluble enzymes secreted from epithelial cells (14).
Moreover, HBV-BF hampered the reactivity of the preserum HBV-BF in the membranes of normal human hepatocytes (5). The membrane-type matrix metallo-S-specific MAbs with the corresponding epitopes on the L HBV protein. Since (i) this effect was prevented by proteinases exist also as HBV-BF in both membrane bound and soluble, truncated forms of a molecular metalloproteinase inhibitors and (ii) the intact L protein could be evidenced by Western blot, it is conceivable mass of about 50 kDa (2, 31). Our findings are consistent with recently published that cleavage of the M protein by HBV-BF affected the conformation of the large HBV protein. The HBV-BF-didata by Lu et al. (18) , who showed that HBV digested with streptococcal V8 protease can efficiently infect the gested virus remained morphologically unchanged and conserved its intact conformation-dependent S domain human hepatoblastoma cell line HepG2, refractive to infection with native HBV. The authors suggested that the reactivity. Whether all these structural changes induced by HBV-BF exposed potential N-terminal fusogenic selack of the suitable fusion-activation protease could be responsible for the lack of susceptibility of this cell line quence of HBV-S protein is at present under investigation.
to HBV infection. We therefore believe that the host-dependent proteolytic activation of the virus contributes to The human CD4
/ T-lymphocyte cell line, CEM only weakly bound native HBV and much more efficiently rethe entry of HBV into the cell. This mechanism would implicate a fusogenic process presumably through a cell combinant S,L* HBsAg particles composed of the major S protein and of a truncated L* protein containing presurface interaction with the newly exposed sites of the viral envelope. A neutral metalloproteinase identical or S1 (12-52) and pre-S2 (133-145) aa sequences (32) as previously demonstrated by our group by immunofluoresrelated to HBV-BF is a good candidate for the enzyme involved in the proteolytic activation which can be of cent techniques (35). In this study the CEM cells did not (or very weakly) adsorb and internalize the native virus, importance for the spread of HBV infection. The availability of the activating proteinase in a membrane-bound or in contrast with the metalloproteinase (HBV-BF)-digested virions. Therefore, the proteolytic activation of the envesecreted form might be determining for HBV host range and/or tissue tropism. Metalloproteinases are particulope proteins by HBV-BF enabled HBV binding to the cell surface and viral entry into the cell.
larly abundant at the apical surface of the epithelial cells in the digestive and respiratory tracts and have been The substrate specificity and other enzymatic properties of the HBV-BF suggested that this molecule is a reported to be involved in the entry of other mammalian viruses into cells (43). member of the matrix metalloproteinase (MMP) family. MMPs are zinc requiring matrix-degrading enzymes The conformational changes induced by exposure to low pH provide an efficient mechanism of entry of many which include collagenases, gelatinases, and stromelysins, all of which are involved in the physiological as pH-dependent viruses (21) . A number of other enveloped viruses do not require exposure to acid pH for entry and well as pathological remodeling of the extracellular matrix (3). MMPs are secreted as catalytically latent a protease might function as a fusion trigger for these pH-independent viruses (21) . The activity of HBV-BF was forms (zymogens). Their activity is tightly controlled by mechanisms of proteolytic activation and modulated highest at neutral pH, and sharply decreased with acid pH. Moreover, the metalloproteinase-digested virus by tissue inhibitors of matrix metalloproteinases in the pericellular and extracellular environments. (3) . Two could enter the cell without exposure to low pH. Therefore HBV may also in vivo enter the cell by a pH-indepencollagen degrading enzymes MMP-1 and MMP-2 were detected in normal and fibrosis livers (24). Recently, dent mechanisms; e.g., by direct fusion between the viral envelope and the plasma membrane. new members of this family, the membrane-associated ectoenzymes were discovered and named ''the memThe detection of viral antigens and HBV DNA in peripheral blood mononuclear cells during the natural course brane-type matrix metalloproteinases'' (MT-MMP-1, -2, and -3) due to an additional transmembrane domain of infection raises the question whether the viral replication can take place in this type of cell (15, 16). In our (2, 31, 38) . Particular attention has been focused on the ability of some MT-MMPs to induce processing of studies we did not find in the inoculated cells the covalently closed, circular DNA (ccc-DNA), the form of the the MMP-2 zymogen to its activated form (gelatinase) (38) . The substrate specificity of the HBV-BF and its HBV genome considered as the evidence of viral replication, although the same viral preparation under the same capacity to activate MMP-2 suggest that this molecule can also be a membrane-located enzyme. Indeed, it experimental conditions was infectious in a primary culture of normal human hepatocytes (P. Gripon, personal has been recently shown that hepatocytes induce the Lofas, S., Persson, B., Roos, H., and Ronnberg, I. (1991). Realcommunication). These findings suggest that despite vitime biospecific interaction analysis using surface plasmon resral binding and protease-induced internalization, the in onance and a sensor chip technology. 
